Nanobiotix Statistics
Total Valuation
Nanobiotix has a market cap or net worth of EUR 236.27 million. The enterprise value is 211.55 million.
Market Cap | 236.27M |
Enterprise Value | 211.55M |
Important Dates
The next estimated earnings date is Friday, September 13, 2024.
Earnings Date | Sep 13, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Nanobiotix has 47.40 million shares outstanding. The number of shares has increased by 6.23% in one year.
Shares Outstanding | 47.40M |
Shares Change (YoY) | +6.23% |
Shares Change (QoQ) | +0.14% |
Owned by Insiders (%) | 2.70% |
Owned by Institutions (%) | 21.45% |
Float | 22.81M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 5.08 |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -5.33 |
EV / Sales | 5.84 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -16.52 |
Financial Position
The company has a current ratio of 1.75
Current Ratio | 1.75 |
Quick Ratio | 1.68 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | -3.95 |
Interest Coverage | -3.04 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -19.72% |
Return on Capital (ROIC) | -40.48% |
Revenue Per Employee | 354,980 |
Profits Per Employee | -389,216 |
Employee Count | 102 |
Asset Turnover | 0.47 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -42.38% in the last 52 weeks. The beta is 1.29, so Nanobiotix's price volatility has been higher than the market average.
Beta (5Y) | 1.29 |
52-Week Price Change | -42.38% |
50-Day Moving Average | 4.69 |
200-Day Moving Average | 5.64 |
Relative Strength Index (RSI) | 58.14 |
Average Volume (20 Days) | 64,135 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Nanobiotix had revenue of EUR 36.21 million and -39.70 million in losses. Loss per share was -1.08.
Revenue | 36.21M |
Gross Profit | 36.21M |
Operating Income | -24.24M |
Pretax Income | -39.58M |
Net Income | -39.70M |
EBITDA | -23.69M |
EBIT | -24.24M |
Loss Per Share | -1.08 |
Balance Sheet
The company has 75.28 million in cash and 50.57 million in debt, giving a net cash position of 24.72 million or 0.52 per share.
Cash & Cash Equivalents | 75.28M |
Total Debt | 50.57M |
Net Cash | 24.72M |
Net Cash Per Share | 0.52 |
Equity (Book Value) | -1.84M |
Book Value Per Share | -0.04 |
Working Capital | 37.47M |
Cash Flow
In the last 12 months, operating cash flow was -12.48 million and capital expenditures -328,000, giving a free cash flow of -12.80 million.
Operating Cash Flow | -12.48M |
Capital Expenditures | -328,000 |
Free Cash Flow | -12.80M |
FCF Per Share | -0.27 |
Margins
Gross margin is 100.00%, with operating and profit margins of -66.94% and -109.64%.
Gross Margin | 100.00% |
Operating Margin | -66.94% |
Pretax Margin | -109.31% |
Profit Margin | -109.64% |
EBITDA Margin | -65.42% |
EBIT Margin | -66.94% |
FCF Margin | -35.36% |
Dividends & Yields
Nanobiotix does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -6.23% |
Shareholder Yield | -6.23% |
Earnings Yield | -21.67% |
FCF Yield | -5.42% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |